Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Anticardiolipin antibodies and acquired immunodeficiency syndrome: Prognostic marker or association with HIV infection?

Anticardiolipin-Antikörper und erworbenes Immunschwächesyndrom: Prognostischer Marker oder Assoziation mit HIV-Infektion?

  • 33 Accesses

  • 33 Citations


Anticardiolipin antibodies (ACA) frequently appear in patients with autoimmune disorders such as systemic lupus erythematosus, and have also been detected in infections, neoplasia, the primary antiphospholipid syndrome, in association with certain medications and also in subjects without apparent disease. Recently, anticardiolipin antibodies have been described in the acquired immunodeficiency syndrome. Eighty-four human immunodeficiency virus (HIV)-infected patients were studied to assess the influence of risk factors for HIV infection and of the stage of HIV-1 infection on the prevalence of IgG-ACA in HIV-seropositive patients. Patients were divided in two groups, one composed of 38 asymptomatic HIV-infected individuals and the other of 46 AIDS patients. A control group of 42 healthy HIV-negative blood donors was also studied. All subjects of the control group were IgG-ACA-negative. Of the 84 HIV-positive patients, 50 were IgG-ACA positive (59.5%) and 34 IgG-ACA negative (40.5%). None of the HIV-positive patients presented any thromboembolic phenomena. No significant differences were found with respect to sex, risk factors and stage of disease when the presence of IgG-ACA in HIV-positive patients was considered. ACA does not appear to be a pronostic marker in HIV-1-infected subjects. The presence of IgG-ACA is probably related to HIV-1-infection itself, and is indicative of impaired humoral immunity in these patients.


Anticardiolipin-Antikörper (ACA) treten häufig bei Patienten mit Autoimmunkrankheiten wie Lupus erythematodes auf, wurden aber auch im Zusammenhang mit Infektionen, Neoplasien, dem primären Antiphospholipid-Syndrom und bestimmten Medikamenten beobachtet oder bei Personen ohne jegliche erkennbare Erkrankung. Kürzlich wurden Anticardiolipin-Antikörper bei erworbener Immunschwäche beschrieben. Um den Einfluß von Risikofaktoren für eine HIV-Infektion und des Krankheitsstadiums auf die Prävalenz von IgG- ACA zu ermitteln, wurden 84 HIV-infizierte Patienten untersucht. Sie wurden in zwei Gruppen, 38 asymptomatische HIV-Infizierte und 46 AIDS-Patienten unterteilt und mit einer Kontrollgruppe von 42 gesunden, HIV-negativen Blutspendern verglichen. Die Kontrollpersonen waren alle ACA-negativ. Aus der Gesamtgruppe der 84 HIV-positiven Patienten wiesen 50 ACA-IgG auf (59,5%), 34 waren negativ (40,5%). Thromboembolische Phänomene waren bei keinem dieser HIV-positiven Personen zu beobachten. Es bestand keine signifikante Differenz zwischen positiven und negativen ACA-Befunden hinsichtlich Geschlecht der Patienten, Risikofaktoren und Krankheitsstadium der HIV- Infektion. Bei HIV-1-Infizierten scheint der Nachweis von ACA keine prognostische Bedeutung zu haben. Die Antikörper sind wahrscheinlich mit der HIV-Infektion selbst assoziiert und ein Zeichen für die gestörten humoralen Immunfunktionen dieser Patienten.

This is a preview of subscription content, log in to check access.


  1. 1.

    Stimmler, M. M., Quismorio, F. P., McGehee, W. G., Boylen, T., Sharma, O. P. Anticardiolipin antibodies in acquired immunodeficiency syndrome. Arch. Intern. Med. 149 (1989) 1833–1835.

  2. 2.

    Canoso, R. T., Zon, L. I., Groopman, J. E. Anticardiolipin antibodies associated with HTLV-III infection. Br. J. Haematol. 65 (1987) 495–498.

  3. 3.

    Masala, C., Sorice, M., Di Prima, M. A., Lenti, L., Misasi, R., Contini, C., Vullo, V. Anticardiolipin antibodies andPneumocystis carinii pneumonia. Ann. Intern. Med. 110 (1989) 749.

  4. 4.

    Coll, J., Yazbeck, H., Garcés, J. M., Bergés, A., Prats, F., Rubiés-Prat, J. Anticardiolipin antibodies andPneumocystis carinii pneumonia in patients with AIDS. J. Infect. 21 (1990) 120.

  5. 5.

    Centers for Disease Control Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 36 (1987) 3–17.

  6. 6.

    Towbin, H., Staehelin, T., Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. (USA) 76 (1979) 4350–4354.

  7. 7.

    Harris, E. N., Gharavi, A. E., Patel, S. P., Hugues, R. V. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin. Exp. Immunol. 68 (1987) 215–222.

  8. 8.

    Bloom, E. J., Abrams, D. I., Rodgers, G. Lupus anticoagulant in the acquired immunodeficiency syndrome. JAMA 256 (1986) 491–493.

  9. 9.

    Lane, H. C., Masur, H., Edgar, L. C., Whalen, G., Rook, A. H., Fauci, A. S. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309 (1983) 453–458.

  10. 10.

    Kalunian, K. C., Peter, J. B., Middlekauff, H. R., Sayre, J., Ando, D. G., Mangotich, M., Hahn, B. H. Clinical significance of a single test for anticardiolipin antibodies in patients with systemic lupus erythematosus. Am. J. Med. 85 (1988) 602–608.

  11. 11.

    Misra, R., Venables, P. J., Watkins, R. P., Maini, R. N. Autoimmunity to cardiolipin in infectious mononucleosis. Lancet ii (1987) 629.

  12. 12.

    McNeil, H. P., Simpson, R. J., Chesterman, C. N., Krilis, S. A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-Glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. (USA) 87 (1990) 4120–4124.

  13. 13.

    Harris, N. E., Pierangeli, S. What is the “true” antigen for antiphospholipid antibodies? Lancet i (1990) 1505.

  14. 14.

    Mulhall, B. P., Naselli, G., Whittingham, S. Anticardiolipin antibodies in homosexual men: prevalence and lack of association with HIV infection. J. Clin. Immunol. 9 (1989) 208–213.

Download references

Author information

Correspondence to Dr. J. Coll Daroca M.D..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Daroca, J.C., Gutiérrez-Cabollada, J., Yazbeck, H. et al. Anticardiolipin antibodies and acquired immunodeficiency syndrome: Prognostic marker or association with HIV infection?. Infection 20, 140–142 (1992). https://doi.org/10.1007/BF01704601

Download citation


  • Human Immunodeficiency Virus
  • Systemic Lupus Erythematosus
  • Human Immunodeficiency Virus Infection
  • Prognostic Marker
  • Blood Donor